CL2011001034A1 - Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras. - Google Patents

Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.

Info

Publication number
CL2011001034A1
CL2011001034A1 CL2011001034A CL2011001034A CL2011001034A1 CL 2011001034 A1 CL2011001034 A1 CL 2011001034A1 CL 2011001034 A CL2011001034 A CL 2011001034A CL 2011001034 A CL2011001034 A CL 2011001034A CL 2011001034 A1 CL2011001034 A1 CL 2011001034A1
Authority
CL
Chile
Prior art keywords
compounds
menorrhagia
endometriosis
pyrrolidine
diseases
Prior art date
Application number
CL2011001034A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Neil Dack
James Edward John Mill
Sarah Elizabeth Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CL2011001034A1 publication Critical patent/CL2011001034A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2011001034A 2008-11-10 2011-05-09 Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras. CL2011001034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11286908P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
CL2011001034A1 true CL2011001034A1 (es) 2011-11-11

Family

ID=41503565

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001034A CL2011001034A1 (es) 2008-11-10 2011-05-09 Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.

Country Status (31)

Country Link
US (1) US8278343B2 (enExample)
EP (1) EP2364296A1 (enExample)
JP (1) JP2012508225A (enExample)
KR (1) KR20110083733A (enExample)
CN (1) CN102209710A (enExample)
AP (1) AP2011005728A0 (enExample)
AR (1) AR074314A1 (enExample)
AU (1) AU2009312427B2 (enExample)
BR (1) BRPI0920924A2 (enExample)
CA (1) CA2741589A1 (enExample)
CL (1) CL2011001034A1 (enExample)
CO (1) CO6382112A2 (enExample)
CR (1) CR20110217A (enExample)
CU (1) CU20110093A7 (enExample)
DO (1) DOP2011000127A (enExample)
EA (1) EA201100549A1 (enExample)
EC (1) ECSP11011032A (enExample)
GE (1) GEP20125607B (enExample)
IL (1) IL212490A0 (enExample)
MA (1) MA32782B1 (enExample)
MX (1) MX2011004903A (enExample)
NI (1) NI201100092A (enExample)
NZ (1) NZ592311A (enExample)
PA (1) PA8848001A1 (enExample)
PE (1) PE20110663A1 (enExample)
SV (1) SV2011003896A (enExample)
TN (1) TN2011000211A1 (enExample)
TW (1) TW201022234A (enExample)
UY (1) UY32228A (enExample)
WO (1) WO2010052625A1 (enExample)
ZA (1) ZA201104310B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JPWO2013176220A1 (ja) * 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
JP2024524986A (ja) 2021-06-24 2024-07-09 レザボア ニューロサイエンス,インコーポレイテッド Ep2アンタゴニスト化合物
EP4359399A4 (en) * 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646722B2 (en) * 1991-01-21 1994-03-03 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone analog
AU2002358772B2 (en) * 2001-12-20 2008-11-20 Merck Serono Sa Pyrrolidine derivatives as prostaglandin modulators
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
DE102006039912A1 (de) * 2006-08-25 2008-03-20 Bayer Healthcare Ag Substituierte Spirotetronsäuren und ihre Verwendung
AU2008249744A1 (en) * 2007-05-10 2008-11-20 Pfizer Limited Azetidine derivatives and their use as prostaglandin E2 antagonists

Also Published As

Publication number Publication date
TW201022234A (en) 2010-06-16
PE20110663A1 (es) 2011-09-23
US8278343B2 (en) 2012-10-02
DOP2011000127A (es) 2011-07-15
ECSP11011032A (es) 2011-06-30
PA8848001A1 (es) 2010-06-28
CN102209710A (zh) 2011-10-05
EA201100549A1 (ru) 2011-12-30
UY32228A (es) 2010-06-30
ZA201104310B (en) 2012-02-29
SV2011003896A (es) 2011-07-05
US20100120793A1 (en) 2010-05-13
GEP20125607B (en) 2012-08-10
EP2364296A1 (en) 2011-09-14
AP2011005728A0 (en) 2011-06-30
AU2009312427B2 (en) 2011-10-20
AU2009312427A1 (en) 2010-05-14
JP2012508225A (ja) 2012-04-05
BRPI0920924A2 (pt) 2016-10-04
MA32782B1 (fr) 2011-11-01
AR074314A1 (es) 2011-01-05
MX2011004903A (es) 2011-05-30
IL212490A0 (en) 2011-06-30
WO2010052625A1 (en) 2010-05-14
CU20110093A7 (es) 2012-01-31
CR20110217A (es) 2011-05-12
CA2741589A1 (en) 2010-05-14
NI201100092A (es) 2011-10-31
KR20110083733A (ko) 2011-07-20
NZ592311A (en) 2012-12-21
TN2011000211A1 (fr) 2012-12-17
CO6382112A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
CL2008000899A1 (es) Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
CL2012002733A1 (es) Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2008002268A1 (es) Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2008003694A1 (es) Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica.
EA201071320A1 (ru) Активаторы глюкокиназы
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.